#1 Ranked Children’s Hospital by U.S. News & World Report
MyPatients provides referring primary care providers with secure access to their patients’ information.
Boston Children's has launched the world's 1st program dedicated to offering hand transplants to children who qualify.
Innovation insider is a semi-monthly e-newsletter analyzes innovations at Boston Children’s, other academic medical centers and from industry.
Read the latest blog by a Boston Children's doctor, clinician or staff member.
There are many ways you can help children and their families get the care they need.
Specific treatment for a ganglioglioma will be determined by your child's physician based on:
Children with gangligliomas may have side effects related to the tumor itself and its treatment. Symptoms at the time of diagnosis related to increased pressure within the brain, such as headache, vomiting and lethargy, and/or from compression of the nerves that control movement of the extremities, are often relieved by surgical debulking of the tumor. Dexamethasone, an oral steroid, is often used, especially in the post-operative period, to assist in controlling symptoms of increased pressure within the brain, as well as any additional tissue swelling that may occur post-operatively.
Radiation therapy may cause swelling related to tissue inflammation. This inflammation may lead to symptoms of headache or difficulty with coordination. These symptoms, if significant, may be treated with the oral medication dexamethasone.
Children with seizures are treated with anti-seizure medications to control or, in some cases, eliminate these symptoms.
Gangliogliomas are associated with a high rate of cure. Data suggest a 20-year survival rate of approximately 80 percent. Greater degree of surgical removal is associated with a higher rate of cure.
The recommended treatment for progressive/recurrent ganglioglioma is radiation therapy. Dana-Farber Cancer Institute is one of nine institutes in the nation belonging to the Pediatric Brain Tumor Consortium. The consortium is dedicated to the development of new and innovative treatments for children with progressive/recurrent brain tumors not responsive to standard therapies. Children with progressive/recurrent ganglioglioma would be eligible for a number of experimental therapies available through the consortium.
We are grateful to have been ranked #1 on U.S. News & World Report's list of the best children's hospitals in the nation for the third year in a row, an honor we could not have achieved without the patients and families who inspire us to do our very best for them. Thanks to you, Boston Children's is a place where we can write the greatest children's stories ever told.”